Answers are grounded in this paper and cite their sources.
Assess the impact of one year of gender-affirming hormone therapy on body composition, muscle strength, metabolic and hormonal parameters in transgender men. Prospective, observational cohort study. 64 participants completed one year of follow-up. Assessments were performed at baseline, six months and one year, and included anthropometry, bioelectrical impedance analysis, hand grip strength, quadriceps ultrasound, and blood tests. Participants received testosterone therapy according to international clinical guidelines, with dietary and lifestyle counselling during this process. After one year of treatment with testosterone, participants demonstrated significant increases in both skeletal muscle mass (2.45 ± 1.85 kg 13.4% increase, p < 0.001) and hand grip strength (25.3% increase, p < 0.001), together with significant reductions in total fat mass (20.7% decrease, p < 0.001), and visceral adiposity (33.3% decrease, p < 0.001). Changes in muscle and fat mass were significant at 6 months, while hand grip strength became significant after one year. Type of testosterone prescription influenced muscle mass gain, while using of gonadotropin releasing hormone analogues did not significantly influence body composition outcomes. Regarding biochemical changes, participants showed a decrease of 6.50 (1.00; 11.00) mg/dL in high density lipoprotein cholesterol levels ( p < 0.001), and a reduction of 23.0 (6.5; 35.0) mg/dL in Apo A1 levels ( p < 0.01). Hemoglobin levels increased by 1.90 (1.40; 2.60) g/dL ( p < 0.001), and hematocrit by 5.15 (3.40; 7.30) % ( p < 0.001). Concerning body composition, participants Quadriceps ultrasound showed a high accuracy for detecting both low skeletal muscle mass and appendicular skeletal muscle mass (AUC > 0.85). Gender-affirming hormone therapy in transgender men improves muscle mass, strength, and body fat distribution, with testosterone-type–specific patterns of change. Furthermore, these preliminary findings suggest that quadriceps ultrasound may have potential as a non-invasive, accessible tool for indirectly quantifying muscle mass during testosterone treatment, but further validation is required before clinical application.
No takes yet. Share an insight, caveat, or question.
Bosch‐Sierra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: